IBISBA 1.0 project


Industrial Biotechnology Innovation and Synthetic Biology Accelerator

This project entitled Industrial Biotechnology Innovation and Synthetic Biology Accelerator 1.0, aims to create a coordinated network of research infrastructure facilities that support industrial biotechnology. The work of the network is to open access to first-rate research facilities and lay the foundations for a permanent research infrastructure that will address some of the main challenges that are currently hampering the development of industrial biotechnology, a key enabling technology (KET) of Europe’s bioeconomy.

The IBISBA 1.0 consortium is composed of 16 organisations from 9 different European member states, working together to promote industrial biotechnology: Institut National de la Recherche Agronomique (France), Institut National des Sciences Appliquees De Toulouse (France), Vlaamse Instelling Voor Technologisch Onderzoek N.V. (Belgium), Universite de Nantes (France), Fraunhofer Gesellschaft Zur Foerderung der Angewandten Forschung E.V. (Germany), Teknologian Tutkimuskeskus Vtt Oy (Finland), Universitat Autonoma de Barcelona (Spain), Consiglio Nazionale delle Ricerche (Italy), National Technical University of Athens - Ntua (Greece), Commissariat A L Energie Atomique et Aux Energies Alternatives (France), Agencia Estatal Consejo Superior de Investigaciones Cientificas (Spain), The University of Manchester (United Kingdom), Knime.Com Gmbh (Germany), Wageningen University (Netherlands), Lifeglimmer Gmbh (Germany), Inra Transfert S.A. (France).

IBISBA 1.0 is aiming to offer top class services to potential users coming from both public and private sectors, irrespective of whether they are located in a European Union member state or not. Additionally, IBISBA 1.0 wants to supply users with an integrated service offer that will move user projects as far along the innovation continuum as possible. To achieve this, IBISBA 1.0 can mobilize a wide range of research tools and expertise.

2017 - 2018

The project has received 5 milions funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement n. 730976.